

Clinical trials of E-CMM

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
E-CMM vs placebo			
ENACT-AMI <i>ongoing</i> n=NA follow-up:	autologous E-CMMs (culture modified circulating mononuclear cells), or E-CMMs transfected with human endothelial nitric oxide synthase delivered by coronary injection into the infarct-related artery versus placebo	-	

More details and results :

- cell-based therapies for acute myocardial infarction in PCI at <http://www.trialresultscenter.org/go-Q313>

References

ENACT-AMI, :

ongoing trial

Taljaard M, Ward MR, Kutryk MJ, Courtman DW, Camack NJ, Goodman SG, Parker TG, Dick AJ, Galipeau J, Stewart DJ Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. *Am Heart J* 2010;159:354-60 [20211295] [10.1016/j.ahj.2009.12.021](https://doi.org/10.1016/j.ahj.2009.12.021)